# [177Lu]-NeoB in Patients With Advanced Solid Tumors and With [68Ga]-neoB Lesion Uptake

> **NCT03872778** · PHASE1,PHASE2 · COMPLETED · sponsor: **Advanced Accelerator Applications** · enrollment: 35 (actual)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** [177Lu]-NeoB
- **DRUG:** [68Ga]-NeoB
- **DRUG:** LCZ696

## Key facts

- **NCT ID:** NCT03872778
- **Lead sponsor:** Advanced Accelerator Applications
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-24
- **Primary completion:** 2025-01-07
- **Final completion:** 2025-11-27
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2026-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03872778

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03872778, "[177Lu]-NeoB in Patients With Advanced Solid Tumors and With [68Ga]-neoB Lesion Uptake". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT03872778. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*